Sortera Bio, a Cambridge biotech based on IP developed at the MRC Laboratory of Molecular Biology, has attracted big hitting ...

The AstraZeneca PLC ADR AZN rose 1.64% to $73.00 Wednesday, on what proved to be an all-around mixed trading session for the ...

Drugmakers unveil cancer drug data at the ASCO annual meeting, while Amazon Pharmacy announces new features for caregivers, ...

AstraZeneca PLC closed 19.58% short of its 52-week high of £133.88, which the company reached on September 3rd.

Camizestrant will reach blockbuster status in 2030 with total sales worth $1.1 billion, according to GlobalData’s analyst ...

The latest trading session saw Astrazeneca (AZN) ending at $71.93, denoting a -1.24% adjustment from its last day's close.

AstraZeneca (LSE:AZN) recently announced promising clinical trial results for ENHERTU, which may reflect its ongoing ...

AstraZeneca Plc and Daiichi Sankyo Co.’s Enhertu delayed the advance of a common type of breast cancer by more than a year in ...

Drugmaker AstraZeneca has agreed to pay $50.9 million to settle a class action lawsuit in U.S. court accusing the company of ...

AstraZeneca Plc (NASDAQ:AZN) on Monday released results from three Phase 3 clinical trials at the 2025 American Society of ...

Treating breast cancer patients with AstraZeneca's experimental pill camizestrant at the first sign of resistance to standard ...

AstraZeneca CEO Pascal Soriot views the company's stock price — up just 10% year-to-date — as a marker of how he is doing. He ...